Login to Your Account

Syntonix, Biovitrum In Deal On Long-Acting Clotting Product

By Aaron Lorenzo

Tuesday, January 24, 2006
Syntonix Pharmaceuticals Inc. agreed to out-license overseas rights to FIX:Fc, its preclinical recombinant Factor IX product for hemophilia B, to Biovitrum AB. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription